{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:09:26Z","timestamp":1790392166134,"version":"4.1.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41375-025-02753-w","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:11:03Z","timestamp":1760094663000},"page":"120-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3858-3157","authenticated-orcid":false,"given":"Jesse","family":"Geels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"van Rhenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Gradowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert W.","family":"Asselbergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Linschoten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"2753_CR1","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","DOI":"10.1038\/s41408-021-00425-3"},{"key":"2753_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","volume":"394","author":"H Strongman","year":"2019","unstructured":"Strongman H, Gadd S, Matthews A, Mansfield KE, Stanway S, Lyon AR, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019;394:1041\u201354.","journal-title":"Lancet"},{"key":"2753_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jaccao.2022.01.100","volume":"4","author":"DI Paterson","year":"2022","unstructured":"Paterson DI, Wiebe N, Cheung WY, Mackey JR, Pituskin E, Reiman A, et al. Incident cardiovascular disease among adults with cancer. JACC Cardio Oncol. 2022;4:85\u201394.","journal-title":"JACC Cardio Oncol"},{"key":"2753_CR4","doi-asserted-by":"publisher","first-page":"101830","DOI":"10.1016\/j.esmoop.2023.101830","volume":"8","author":"JD Mitchell","year":"2023","unstructured":"Mitchell JD, Laurie M, Xia Q, Dreyfus B, Jain N, Jain A, et al. Risk profiles and incidence of cardiovascular events across different cancer types. ESMO Open. 2023;8:101830\u20130.","journal-title":"ESMO Open"},{"key":"2753_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jaccao.2023.07.007","volume":"5","author":"A Vasbinder","year":"2023","unstructured":"Vasbinder A, Hoeger CW, Catalan T, Anderson E, Chu CJ, Kotzin M, et al. Cardiovascular events after hematopoietic stem cell transplant: incidence and risk factors. JACC Cardio Oncol. 2023;5:821\u201332.","journal-title":"JACC Cardio Oncol"},{"key":"2753_CR6","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.bbmt.2014.02.012","volume":"20","author":"EJ Chow","year":"2014","unstructured":"Chow EJ, Wong K, Lee SJ, Cushing-Haugen KL, Flowers MED, Friedman DL, et al. Late cardiovascular complications after hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2014;20:794\u2013800.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2753_CR7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaccao.2020.06.011","volume":"2","author":"RJ Massey","year":"2020","unstructured":"Massey RJ, Diep PP, Ruud E, Burman MM, Kvaslerud AB, Brinch L, et al. Left ventricular systolic function in long-term survivors of allogeneic hematopoietic stem cell transplantation. JACC Cardio Oncol. 2020;2:460\u201371.","journal-title":"JACC Cardio Oncol"},{"key":"2753_CR8","doi-asserted-by":"crossref","unstructured":"Auberle C, Lenihan D, Gao F, Cashen A. Late cardiac events after allogeneic stem cell transplant: incidence, risk factors, and impact on overall survival. Cardio Oncol. 2023;9:1.","DOI":"10.1186\/s40959-022-00150-1"},{"key":"2753_CR9","first-page":"237","volume":"4","author":"JB Echouffo-Tcheugui","year":"2016","unstructured":"Echouffo-Tcheugui JB, Erqou S, Butler J, Yancy CW, Fonarow GC. Assessing the risk of progression from asymptomatic left ventricular dysfunction to overt heart failure. JACC: Heart Fail. 2016;4:237\u201348.","journal-title":"JACC: Heart Fail"},{"key":"2753_CR10","doi-asserted-by":"crossref","unstructured":"Wilcox NS, Amit U, Reibel JB, Berlin E, Howell K, Ky B. Cardiovascular disease and cancer: shared risk factors and mechanisms. Nat Rev Cardiol. 2024;21:617\u201331.","DOI":"10.1038\/s41569-024-01017-x"},{"key":"2753_CR11","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/ejhf.2029","volume":"22","author":"R De Boer","year":"2020","unstructured":"De Boer R, Hulot JS, Tocchetti CG, Aboumsallem JP, Ameri P, Anker SD, et al. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22:2272\u201389.","journal-title":"Eur J Heart Fail"},{"key":"2753_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41569-022-00698-6","volume":"19","author":"A Karlstaedt","year":"2022","unstructured":"Karlstaedt A, Moslehi J, de Boer RA. Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer. Nat Rev Cardiol. 2022;19:414\u201325.","journal-title":"Nat Rev Cardiol"},{"key":"2753_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.amjcard.2024.06.033","volume":"226","author":"Y Kang","year":"2024","unstructured":"Kang Y, Lefebvre B, Pamies IM, Gill SI, Doucette AG, Denduluri S, et al. Symptomatic heart failure and clonal hematopoiesis-related mutations in patients with acute myeloid leukemia. Am J Cardiol. 2024;226:9\u201317.","journal-title":"Am J Cardiol"},{"key":"2753_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaccao.2021.11.008","volume":"4","author":"O Calvillo-Arg\u00fcelles","year":"2022","unstructured":"Calvillo-Arg\u00fcelles O, Schoffel A, Capo-Chichi JM, Abdel-Qadir H, Schuh A, Carrillo-Estrada M, et al. Cardiovascular disease among patients with AML and CHIP-related mutations. JACC Cardio Oncol. 2022;4:38\u201349.","journal-title":"JACC Cardio Oncol"},{"key":"2753_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"7","author":"D Cardinale","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26.","journal-title":"Front Cardiovasc Med"},{"key":"2753_CR16","first-page":"485","volume":"57","author":"JW Yates","year":"1973","unstructured":"Yates JW, Wallace HJ, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57:485\u20138.","journal-title":"Cancer Chemother Rep"},{"key":"2753_CR17","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. Blood. 2022;140:1345\u201377.","DOI":"10.1182\/blood.2022016867"},{"key":"2753_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.18.00313","volume":"37","author":"KD Getz","year":"2019","unstructured":"Getz KD, Sung L, Ky B, Gerbing RB, Leger KJ, Leahy AB, et al. Occurrence of treatment-related cardiotoxicity and its impact on outcomes among children treated in the AAML0531 clinical trial: a report from the Children\u2019s Oncology Group. J Clin Oncol: J Am Soc Clin Oncol. 2019;37:12\u201321.","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"2753_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaccao.2019.10.008","volume":"1","author":"Y Kang","year":"2019","unstructured":"Kang Y, Assuncao BL, Denduluri S, McCurdy S, Luger S, Lefebvre B, et al. Symptomatic heart failure in acute leukemia patients treated with anthracyclines. JACC Cardio Oncol. 2019;1:208\u201317.","journal-title":"JACC Cardio Oncol"},{"key":"2753_CR20","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1177\/1078155219873014","volume":"26","author":"MK Mort","year":"2019","unstructured":"Mort MK, Sen JM, Morris AL, DeGregory KA, McLoughlin EM, Mort JF, et al. Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines. J Oncol Pharm Pr. 2019;26:680\u20137.","journal-title":"J Oncol Pharm Pr"},{"key":"2753_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107351","volume":"132","author":"M Stahl","year":"2023","unstructured":"Stahl M, Giblin G, Liu Y, Winer ES, Garcia JS, Chen E, et al. Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia. Leuk Res. 2023;132:107351.","journal-title":"Leuk Res"},{"key":"2753_CR22","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.3390\/cancers15082267","volume":"15","author":"B Boluda","year":"2023","unstructured":"Boluda B, Solana-Altabella A, Cano I, Mart\u00ednez-Cuadr\u00f3n D, Acu\u00f1a-Cruz E, Torres-Mi\u00f1ana L, et al. Incidence and risk factors for development of cardiac toxicity in adult patients with newly diagnosed acute myeloid leukemia. Cancers. 2023;15:2267\u20137.","journal-title":"Cancers"},{"key":"2753_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1200\/JCO.2007.13.2209","volume":"26","author":"MM O\u2019Brien","year":"2008","unstructured":"O\u2019Brien MM, Taub JW, Chang MN, Massey GV, Stine KC, Raimondi SC, et al. Cardiomyopathy in children with down syndrome treated for acute myeloid leukemia: a report from the Children\u2019s Oncology Group Study POG 9421. J Clin Oncol. 2008;26:414\u201320.","journal-title":"J Clin Oncol"},{"key":"2753_CR24","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an Updated Guideline for Reporting Systematic Reviews. Brit Med J. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"2753_CR25","doi-asserted-by":"crossref","unstructured":"Oki T, Takeuchi T, Oka S, Umezawa H. New anthracycline antibiotic aclacinomycin a: experimental studies and correlations with clinical trials. In: Carter, S.K., Sakurai, Y., Umezawa, H. (eds) New Drugs in Cancer Chemotherapy. Recent Results in Cancer Research. Berlin, Heidelberg: Springer Berlin Heidelberg; 1981. pp 21--40.","DOI":"10.1007\/978-3-642-81565-2_4"},{"key":"2753_CR26","first-page":"685","volume":"68","author":"S Hori","year":"1977","unstructured":"Hori S, Shirai M, Hirano S, Oki T, Inui T, Tsukagoshi S, et al. Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity. Gann Japnese J Cancer Res. 1977;68:685\u201390.","journal-title":"Gann Japnese J Cancer Res"},{"key":"2753_CR27","unstructured":"NCI guidelines for investigators: adverse event reporting requirements for DCTD (CTEP AND CIP) and DCP INDs and IDEs. 2013. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/aeguidelines.pdf."},{"key":"2753_CR28","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1214\/aoms\/1177729756","volume":"21","author":"MF Freeman","year":"1950","unstructured":"Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950;21:607\u201311.","journal-title":"Ann Math Stat"},{"key":"2753_CR29","doi-asserted-by":"crossref","unstructured":"Viechtbauer W. Conducting Meta-Analyses in R with the metafor package. J Stat Softw. 2010;36:1\u201348.","DOI":"10.18637\/jss.v036.i03"},{"key":"2753_CR30","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"2753_CR31","doi-asserted-by":"publisher","first-page":"e073725","DOI":"10.1136\/bmj-2022-073725","volume":"381","author":"DR Junqueira","year":"2023","unstructured":"Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, et al. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials. BMJ. 2023;381:e073725.","journal-title":"BMJ"},{"key":"2753_CR32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.leu.2403336","volume":"18","author":"J Holowiecki","year":"2004","unstructured":"Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004;18:989\u201397.","journal-title":"Leukemia"},{"key":"2753_CR33","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/annonc\/mdr346","volume":"23","author":"U Brunnberg","year":"2012","unstructured":"Brunnberg U, Mohr M, Noppeney R, D\u00fcrk HA, Sauerland MC, M\u00fcller-Tidow C, et al. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. Ann Oncol. 2012;23:990\u20136.","journal-title":"Ann Oncol"},{"key":"2753_CR34","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1200\/JCO.2011.37.1286","volume":"30","author":"J Holowiecki","year":"2012","unstructured":"Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012;30:2441\u20138.","journal-title":"J Clin Oncol"},{"key":"2753_CR35","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1182\/bloodadvances.2021004233","volume":"5","author":"AR Walker","year":"2021","unstructured":"Walker AR, Marcucci G, Yin J, Blum W, Stock W, Kohlschmidt J, et al. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv. 2021;5:2775\u201387.","journal-title":"Blood Adv"},{"key":"2753_CR36","doi-asserted-by":"publisher","first-page":"e879","DOI":"10.1016\/S2352-3026(23)00273-9","volume":"10","author":"M L\u00fcbbert","year":"2023","unstructured":"L\u00fcbbert M, Wijermans PW, Kicinski M, Chantepie S, Van der Velden WJFM, Noppeney R, et al. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. Lancet Haematol. 2023;10:e879\u201389.","journal-title":"Lancet Haematol"},{"key":"2753_CR37","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/0277-5379(91)90181-C","volume":"27","author":"F Mandelli","year":"1991","unstructured":"Mandelli F, Petti MC, Ardia A, Di Pietro N, Di Raimondo F, Ganzina F, et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. Eur J Cancer Clin Oncol. 1991;27:750\u20135.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"2753_CR38","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.1992.10.7.1103","volume":"10","author":"WR Vogler","year":"1992","unstructured":"Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol. 1992;10:1103\u201311.","journal-title":"J Clin Oncol"},{"key":"2753_CR39","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","volume":"364","author":"B L\u00f6wenberg","year":"2011","unstructured":"L\u00f6wenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364:1027\u201336.","journal-title":"N Engl J Med"},{"key":"2753_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.34172\/PS.2023.28","volume":"30","author":"A El Zeiny","year":"2023","unstructured":"El Zeiny A, Abdel-Fattah R, Abbassie M, Farid S. Idarubicin versus doxorubicin in acute myeloid leukemia: a parallel randomized trial with pharmacoeconomic analysis. Pharm Sci. 2023;30:135\u201342.","journal-title":"Pharm Sci"},{"key":"2753_CR41","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","volume":"361","author":"B L\u00f6wenberg","year":"2009","unstructured":"L\u00f6wenberg B, Ossenkoppele GJ, Van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235\u201348.","journal-title":"N Engl J Med"},{"key":"2753_CR42","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2352-3026(18)30231-X","volume":"6","author":"N Frey","year":"2019","unstructured":"Frey N, Jang JH, Szer J, Ill\u00e9s \u00c1, Kim HJ, Ram R, et al. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematol. 2019;6:e122\u201331.","journal-title":"Lancet Haematol"},{"key":"2753_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41375-023-02073-x","volume":"38","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, Radich JP, Fang M, et al. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia. 2023;38:58\u201366.","journal-title":"Leukemia"},{"key":"2753_CR44","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1365-2141.1991.tb08049.x","volume":"79","author":"JAL Yin","year":"1991","unstructured":"Yin JAL, Johnson PRE, Davies JM, Flanagan NG, Gorst DW, Lewis MJ. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol. 1991;79:415\u201320.","journal-title":"Br J Haematol"},{"key":"2753_CR45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/10428199309147372","volume":"9","author":"JD Shepherd","year":"1993","unstructured":"Shepherd JD, Reece DE, Barnett MJ, Klingemann HG, Nantel SH, Sutherland HJ, et al. Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide. Leuk Lymphoma. 1993;9:211\u20135.","journal-title":"Leuk Lymphoma"},{"key":"2753_CR46","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/sj.leu.2400623","volume":"11","author":"E Feldman","year":"1997","unstructured":"Feldman E, Seiter K, Damon L, Linker C, Rugo H, Ries C, et al. A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia. 1997;11:485\u20139.","journal-title":"Leukemia"},{"key":"2753_CR47","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/10428190009087021","volume":"38","author":"EJ Feldman","year":"2000","unstructured":"Feldman EJ, Seiter K, Traganos F, Darzynkiewicz Z, Goff H, Pozzuoli M, et al. Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia. Leuk Lymphoma. 2000;38:309\u201315.","journal-title":"Leuk Lymphoma"},{"key":"2753_CR48","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/10428190400013076","volume":"46","author":"A Grigg","year":"2005","unstructured":"Grigg A, Reynolds J, McQuillan A, Juneja S, Iulio JD, Hui C, et al. Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine. Leuk Lymphoma. 2005;46:367\u201375.","journal-title":"Leuk Lymphoma"},{"key":"2753_CR49","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/echo.13245","volume":"33","author":"AY Shaikh","year":"2016","unstructured":"Shaikh AY, Suryadevara S, Tripathi A, Ahmed M, Kane JL, Escobar J, et al. Mitoxantrone-induced cardiotoxicity in acute myeloid leukemia-a velocity vector imaging analysis. Echocardiography. 2016;33:1166\u201377.","journal-title":"Echocardiography"},{"key":"2753_CR50","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41375-018-0268-9","volume":"32","author":"J Braess","year":"2018","unstructured":"Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, et al. Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia\u2014a phase 3 study. Leukemia. 2018;32:2558\u201371.","journal-title":"Leukemia"},{"key":"2753_CR51","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.3109\/10428194.2014.963074","volume":"56","author":"J Jin","year":"2014","unstructured":"Jin J, Chen J, Suo S, Qian W, Meng H, Mai W, et al. Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia. Leuk Lymphoma. 2014;56:1691\u20137.","journal-title":"Leuk Lymphoma"},{"key":"2753_CR52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12185-009-0473-4","volume":"91","author":"Y Morita","year":"2010","unstructured":"Morita Y, Kanamaru A, Miyazaki Y, Imanishi D, Yagasaki F, Tanimoto M, et al. Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. Int J Hematol. 2010;91:97\u2013103.","journal-title":"Int J Hematol"},{"key":"2753_CR53","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1023\/A:1008235801218","volume":"9","author":"P Staib","year":"1998","unstructured":"Staib P, Lathan B, Kn\u00f6ppel-Schwark S, Tesch H, Voliotis D, Steinmetz HT, et al. Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients. Ann Oncol. 1998;9:221\u20133.","journal-title":"Ann Oncol"},{"key":"2753_CR54","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97:2869\u201379.","journal-title":"Cancer"},{"key":"2753_CR55","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Von Hoff","year":"1979","unstructured":"Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-lnduced congestive heart failure. Ann Intern Med. 1979;91:710.","journal-title":"Ann Intern Med"},{"key":"2753_CR56","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1542\/peds.2007-0575","volume":"121","author":"SM Shankar","year":"2008","unstructured":"Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the cardiovascular disease task force of the Children\u2019s Oncology Group. Pediatrics. 2008;121:e387\u201396.","journal-title":"Pediatrics"},{"key":"2753_CR57","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37:2768\u2013801.","journal-title":"Eur Heart J"},{"key":"2753_CR58","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981\u20138.","journal-title":"Circulation"},{"key":"2753_CR59","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10741-019-09860-8","volume":"25","author":"L Grosman-Rimon","year":"2019","unstructured":"Grosman-Rimon L, Billia F, Wright E, Carasso S, Elbaz-Greener G, Kachel E, et al. Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure. Heart Fail Rev. 2019;25:685\u2013701.","journal-title":"Heart Fail Rev"},{"key":"2753_CR60","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1016\/j.clml.2019.03.007","volume":"19","author":"O Pasvolsky","year":"2019","unstructured":"Pasvolsky O, Morelli O, Rozovski U, Vaturi M, Wolach O, Amitai I, et al. Anthracycline-induced cardiotoxicity in acute myeloid leukemia patients who undergo allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2019;19:e343\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2753_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106951","volume":"121","author":"S Fujiwara","year":"2022","unstructured":"Fujiwara S, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Toda Y, et al. Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation. Leuk Res. 2022;121:106951.","journal-title":"Leuk Res"},{"key":"2753_CR62","doi-asserted-by":"crossref","unstructured":"Fabiani I, Chianca M, Cipolla CM, Cardinale DM. Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment. Nat Rev Cardiol. 2025;22:551\u201363.","DOI":"10.1038\/s41569-025-01126-1"},{"key":"2753_CR63","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11739-020-02508-8","volume":"16","author":"F Caspani","year":"2021","unstructured":"Caspani F, Tralongo AC, Campiotti L, Asteggiano R, Guasti L, Squizzato A. Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis. Intern Emerg Med. 2021;16:477\u201386.","journal-title":"Intern Emerg Med"},{"key":"2753_CR64","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy\u2013induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474\u201381.","journal-title":"Circulation"},{"key":"2753_CR65","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jama.2023.11887","volume":"330","author":"TG Neilan","year":"2023","unstructured":"Neilan TG, Quinaglia T, Onoue T, Mahmood S, Drobni Z, Gilman H, et al. Atorvastatin for anthracycline-associated cardiac dysfunction. JAMA. 2023;330:528\u20138.","journal-title":"JAMA"},{"key":"2753_CR66","doi-asserted-by":"publisher","unstructured":"Hundley WG, D\u2019Agostino RB, Crotts T, Craver K, Hackney MH, Jordan JH, et al. Statins and left ventricular ejection fraction following doxorubicin treatment. NEJM Evid. 2022;1. https:\/\/doi.org\/10.1056\/evidoa2200097.","DOI":"10.1056\/evidoa2200097"},{"key":"2753_CR67","doi-asserted-by":"crossref","unstructured":"Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, et al. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother. 2023;9:515\u201325.","DOI":"10.1093\/ehjcvp\/pvad031"},{"key":"2753_CR68","first-page":"CD014638","volume":"9","author":"EC De Baat","year":"2022","unstructured":"De Baat EC, Mulder RL, Armenian S, Feijen EA, Grotenhuis H, Hudson MM, et al. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database Syst Rev. 2022;9:CD014638.","journal-title":"Cochrane Database Syst Rev"},{"key":"2753_CR69","doi-asserted-by":"crossref","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361.","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"2753_CR70","doi-asserted-by":"crossref","unstructured":"Linschoten M, Geels J, van Werkhoven E, Visser-Wisselaar H, Chamuleau MED, Teske AJ, et al. Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane. Cardio Oncol. 2025;11:8.","DOI":"10.1186\/s40959-025-00303-y"},{"key":"2753_CR71","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","volume":"109","author":"D Cardinale","year":"2004","unstructured":"Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749\u201354.","journal-title":"Circulation"},{"key":"2753_CR72","doi-asserted-by":"crossref","unstructured":"Mecinaj A, Gulati G, Ree AH, Gravdehaug B, R\u00f8sj\u00f8 H, Steine K, et al. Impact of the ESC cardio-oncology guidelines biomarker criteria in incidence of cancer therapy\u2013related cardiac dysfunction. JACC Cardio Oncol. 2024.","DOI":"10.1016\/j.jaccao.2023.10.008"},{"key":"2753_CR73","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2459\/JCM.0000000000001589","volume":"25","author":"D Di Lisi","year":"2024","unstructured":"Di Lisi D, Madaudo C, Faro DC, Rossetto L, Triolo OF, Losi V, et al. The added value of the HFA\/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer. J Cardiovasc Med. 2024;25:218\u201324.","journal-title":"J Cardiovasc Med."},{"key":"2753_CR74","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/eurheartj\/ehae496","volume":"46","author":"B Rivero-Santana","year":"2025","unstructured":"Rivero-Santana B, Salda\u00f1a-Garc\u00eda J, Caro-Cod\u00f3n J, Zamora P, Moliner P, Mart\u00ednez Monzonis A, et al. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. 2025;46:273\u201384.","journal-title":"Eur Heart J"},{"key":"2753_CR75","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ijcard.2021.11.059","volume":"349","author":"G Tini","year":"2022","unstructured":"Tini G, Cuomo A, Battistoni A, Sarocchi M, Mercurio V, Ameri P, et al. Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: the HFA\/ICOS risk tool in real-world practice. Int J Cardiol. 2022;349:134\u20137.","journal-title":"Int J Cardiol"},{"key":"2753_CR76","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1200\/JCO.2003.04.100","volume":"21","author":"MC Le Deley","year":"2003","unstructured":"Le Deley MC, Leblanc T, Shamsaldin A, Raquin MA, Lacour B, Sommelet D, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique. J Clin Oncol. 2003;21:1074\u201381.","journal-title":"J Clin Oncol"},{"key":"2753_CR77","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaoncol.2018.6634","volume":"5","author":"EAM Feijen","year":"2019","unstructured":"Feijen EAM, Leisenring WM, Stratton KL, Ness KK, van der Pal HJH, van Dalen EC, et al. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol. 2019;5:864.","journal-title":"JAMA Oncol"},{"key":"2753_CR78","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.clml.2018.08.008","volume":"18","author":"W Owattanapanich","year":"2018","unstructured":"Owattanapanich W, Owattanapanich N, Kungwankiattichai S, Ungprasert P, Ruchutrakool T. Efficacy and toxicity of idarubicin versus high-dose daunorubicin for induction chemotherapy in adult acute myeloid leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2018;18:814\u2013821.e3.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2753_CR79","doi-asserted-by":"publisher","first-page":"e20094","DOI":"10.1097\/MD.0000000000020094","volume":"99","author":"H Wang","year":"2020","unstructured":"Wang H, Xiao X, Xiao Q, Lu Y, Wu Y. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia. Medicine. 2020;99:e20094.","journal-title":"Medicine"},{"key":"2753_CR80","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1200\/JCO.2008.20.6490","volume":"27","author":"F Mandelli","year":"2009","unstructured":"Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009;27:5397\u2013403.","journal-title":"J Clin Oncol"},{"key":"2753_CR81","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1182\/blood-2003-05-1686","volume":"103","author":"JM Rowe","year":"2004","unstructured":"Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103:479\u201385.","journal-title":"Blood"},{"key":"2753_CR82","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249\u201359.","journal-title":"N Engl J Med"},{"key":"2753_CR83","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/blood-2011-06-361410","volume":"118","author":"JH Lee","year":"2011","unstructured":"Lee JH, Joo YD, Kim H, Bae SH, Kim MK, Zang DY, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011;118:3832\u201341.","journal-title":"Blood"},{"key":"2753_CR84","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","volume":"125","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, et al. A randomized comparison of daunorubicin 90 mg\/m 2 vs 60 mg\/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125:3878\u201385.","journal-title":"Blood"},{"key":"2753_CR85","doi-asserted-by":"crossref","unstructured":"R\u00f6llig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, et al. Single or double induction with 7 + 3 containing standard or high-dose daunorubicin for newly diagnosed AML: the randomized daunodouble trial by the study alliance leukemia. J Clin Oncol. 2025;43:65\u201374.","DOI":"10.1200\/JCO.24.00235"},{"key":"2753_CR86","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health. National Cancer Institute. 2017. ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed 21-10-2024."},{"key":"2753_CR87","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1200\/JCO.2011.40.4012","volume":"30","author":"RM Witteles","year":"2012","unstructured":"Witteles RM, Telli M. Underestimating cardiac toxicity in cancer trials: lessons learned?. J Clin Oncol. 2012;30:1916\u20138.","journal-title":"J Clin Oncol"},{"key":"2753_CR88","doi-asserted-by":"crossref","unstructured":"Bonaca MP, Lang NN, Chen A, Amiri-Kordestani L, Lipka L, Zwiewka M, et al. Cardiovascular safety in oncology clinical trials. JACC CardioOncol. 2024;7:83\u201395.","DOI":"10.1016\/j.jaccao.2024.09.014"},{"key":"2753_CR89","doi-asserted-by":"crossref","unstructured":"Harbeck N, Ewer MS, De Laurentiis M, Suter TM, Ewer SM. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Ann Oncol. 2011;22:1250\u20138.","DOI":"10.1093\/annonc\/mdq543"},{"key":"2753_CR90","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF02821937","volume":"15","author":"M Beksa\u00e7","year":"1998","unstructured":"Beksa\u00e7 M, Arslan \u00d6, Ko\u00e7 H, Akan H, Ilhan O, Arat M, et al. Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia. Med Oncol. 1998;15:183\u201390.","journal-title":"Med Oncol"},{"key":"2753_CR91","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","volume":"123","author":"JE Lancet","year":"2014","unstructured":"Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML. Blood. 2014;123:3239\u201346.","journal-title":"Blood"},{"key":"2753_CR92","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481\u201391.","journal-title":"Lancet Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02753-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02753-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02753-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:04:57Z","timestamp":1767985497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02753-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2753"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02753-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6327060\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. This study was based solely on secondary analysis of data from previously published studies; therefore, ethics approval and informed consent were not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}